Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAFTING in early-stage non-bulky classical Hodgkin lymphoma
2020-002382-33Phase 2Active
- Sponsor
- Medical University of Gdańsk
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in classical Hodgkin lymphoma (cHL) (2 cohorts), sponsored by Medical University of Gdańsk. Started Jan 2021; status: active.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2020-002382-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002382-33.